Peptide Improves Cognitive Effects of Traumatic Brain Injury

Posted on: November 14, 2019 in Category: Peptides

1 min read

Cerebrolysin Neuropeptide has been shown in some patients to clinically improve executive function, learning, improved social skills and behavioral adjustments following Mild to Moderate Traumatic Brain Injury.

Cerebrolysin (CBL) is approved for patients with traumatic brain injury (TBI) in Europe, Russia, and China.

TBI leads to transient or chronic impairments in physical, cognitive, emotional and behavioral functions. This is associated with deficits in the recognition of basic emotions, the capacity to interpret the mental states of others, and executive functions.

Cerebrolysin has helped patients improve their clinical outcome when they’ve been given CBL in the acute and subacute phases of mild to moderate traumatic brain injury. Many of these patients improved the quality of their lives following Cerebrolysin therapy.

At the Sand Institute, you may be a candidate for Cerebrolysin Neuropeptide therapy following mild to moderate traumatic brain injury. During your initial consultation, you will learn more about how Cerebrolysin may help you improve your clinical outcome.